HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hearing function after betahistine therapy in patients with Ménière's disease.

AbstractINTRODUCTION:
Preventing or reversing hearing loss is challenging in Ménière's disease. Betahistine, as a histamine agonist, has been tried in controlling vertigo in patients with Ménière's disease, but its effectiveness on hearing problems is not known.
OBJECTIVE:
To examine the effect of betahistine on hearing function in not-previously-treated patients with Ménière's disease and to define possible contributors in this regard.
METHODS:
A total of 200 not-previously-treated patients with definite unilateral Ménière's disease received betahistine by mouth (initial dose, 16mg three times a day; maintenance dose, 24-48mg daily in divided doses). Changes in indicators of hearing status before and six months after treatment were documented. Hearing loss was considered as the mean hearing level >25dB HL at five frequencies.
RESULTS:
The mean duration of disease was 3.37 years. Six months after treatment the mean hearing level decreased by 6.35dB compared to that at the baseline (p<0.001). Both patients' age and the duration of disease correlated negatively with the improvement in hearing function. Post treatment hearing loss was independently associated with age, the initial hearing level and the chronicity of disease. The corresponding optimal cut-off points for predicating a persistent hearing loss 6 months after treatment were 47 years, 38dB HL, and 1.4 years, respectively.
CONCLUSION:
Oral betahistine was significantly effective in preventing/reversing hearing deterioration in patients with Ménière's disease. Age, the hearing level on admission, and the disease duration were independent predictors of hearing status after treatment.
AuthorsSeyed Javad Seyed Tootoonchi, Samad Ghiasi, Parvaneh Shadara, Simin Mirakhor Samani, Daniel Fadaei Fouladi
JournalBrazilian journal of otorhinolaryngology (Braz J Otorhinolaryngol) 2016 Sep-Oct Vol. 82 Issue 5 Pg. 500-6 ISSN: 1808-8686 [Electronic] Brazil
PMID26810620 (Publication Type: Journal Article)
CopyrightCopyright © 2015 Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial. Published by Elsevier Editora Ltda. All rights reserved.
Chemical References
  • Histamine Agonists
  • Betahistine
Topics
  • Adolescent
  • Adult
  • Aged
  • Audiometry
  • Betahistine (therapeutic use)
  • Female
  • Hearing Loss (drug therapy, etiology)
  • Histamine Agonists (therapeutic use)
  • Humans
  • Male
  • Meniere Disease (complications, drug therapy)
  • Middle Aged
  • Otoscopy
  • Treatment Outcome
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: